BIOMS PLANS EXPANSION OF MS TRIAL

BioMS Medical is expanding its clinical development program for its lead drug candidate MBP8298. The drug is currently undergoing an international pivotal Phase II/III clinical trial with secondary progressive multiple sclerosis patients (SPMS). BioMS now plans to initiate a clinical trial for MBP8298 in relapsing-remitting MS (RRMS) patients in the second half of 2006.

MS affects approximately 2.5 million people worldwide, of which 40 to 45 percent have RRMS and 40 to 45 percent have SPMS.